← All compounds
FDA ApprovedFDA Approved

Oxytocin

Neurohypophysial Peptide | Social Bonding & Reproductive Hormone

Oxytocin is a nine-amino-acid peptide hormone and neuropeptide naturally produced in the hypothalamus and released by the posterior pituitary. Known as the "love hormone" or "bonding hormone," it plays fundamental roles in social bonding, trust, empathy, sexual reproduction, childbirth, and lactation. Synthetic oxytocin (Pitocin/Syntocinon) is FDA-approved for labor induction and postpartum hemorrhage control, while intranasal formulations are being researched for autism spectrum disorders, anxiety, depression, PTSD, chronic pain, and sexual dysfunction.

Daily dose

20-40 IU (intranasal)

Frequency

1-2 times daily

Cycle length

4-12 weeks

Storage

2-8°C

Key benefits

FDA-approved for labor induction, extensively researched for social bonding, anxiety reduction, PTSD therapy augmentation, autism spectrum disorders, and sexual function enhancement

How it works

Binds to oxytocin receptors (OXTR) in brain regions involved in social cognition (amygdala, hippocampus, prefrontal cortex) and reproductive tissues. Modulates GABAergic, serotonergic, and dopaminergic neurotransmission. Reduces cortisol and HPA axis activity. Also acts as agonist at opioid receptors and TRPV1 pain receptors.

Dosage protocols

Goal

Social anxiety/bonding enhancement

Dose

20-24 IU · Once daily or before social situations

Route

Intranasal spray

Goal

PTSD therapy augmentation

Dose

40 IU · Before therapy sessions

Route

Intranasal spray

Goal

Sexual function enhancement

Dose

24-40 IU · 30-45 minutes before activity

Route

Intranasal spray

Goal

General wellness/mood

Dose

10-20 IU · Once daily

Route

Intranasal spray

Goal

Sublingual option

Dose

50-100 IU · Once daily

Route

Sublingual troche

Research indications

social

Social Bonding and TrustResearch demonstrates enhanced interpersonal trust, empathy, and in-group bonding. Acts on neural circuits in amygdala and prefrontal cortex.
Autism Spectrum DisordersExtensive research with mixed results. May benefit specific subpopulations; optimal dosing and patient selection remain under investigation.
Social AnxietyStudies show reduced amygdala reactivity to social threats and normalized brain connectivity in social processing regions.

mental

PTSD Therapy AugmentationPromising results when combined with exposure therapy, improving therapeutic alliance and reducing PTSD/depression symptoms.
Anxiety and DepressionEmerging evidence for anxiolytic and antidepressant effects through cortisol reduction and anti-inflammatory pathways.
Schizophrenia Social DeficitsResearch shows potential for improving social cognition and reducing negative symptoms.

reproductive

Labor Induction (FDA Approved)Synthetic oxytocin (Pitocin) is FDA-approved for initiation or augmentation of labor contractions.
Postpartum Hemorrhage (FDA Approved)FDA-approved for control of postpartum bleeding through uterine contraction stimulation.
Sexual FunctionResearch demonstrates improvements in libido, arousal, and orgasm intensity in both men and women.

Administration

injectable
intranasal
oral

Interactions

Monitor Combination
Vasopressin (AVP)Structurally similar peptides (differ by only 2 amino acids) with overlapping receptor affinity. Both act on oxytocin and vasopressin receptors with potential for additive effects.
Synergistic
SelankComplementary anxiolytic effects through different mechanisms. Selank modulates GABA while oxytocin acts on central oxytocin receptors for stress reduction.
Compatible
SemaxNo known interactions. Different mechanisms - Semax for cognitive enhancement, oxytocin for social/emotional support.
Synergistic
PT-141 (Bremelanotide)Complementary effects on sexual function. PT-141 acts on melanocortin receptors while oxytocin enhances bonding, arousal, and orgasm intensity.
Synergistic
KisspeptinBoth involved in reproductive function through different pathways. Kisspeptin stimulates GnRH while oxytocin enhances arousal and bonding.
Compatible
BPC-157No known direct interactions. Different mechanisms - BPC-157 for tissue repair, oxytocin for social/reproductive functions.
Monitor Combination
SSRI AntidepressantsSSRIs may affect endogenous oxytocin levels. Combined use may have additive effects on mood but should be monitored by healthcare provider.
Use Caution
BenzodiazepinesBoth have anxiolytic effects through different mechanisms. Combined use may cause enhanced sedation or additive effects on blood pressure.
Synergistic
ProstaglandinsProstaglandins enhance oxytocin sensitivity in uterine tissue. Often used together clinically for labor induction.
Avoid Combination
AlcoholAlcohol suppresses oxytocin release and may reduce therapeutic effects. Both can affect blood pressure and judgment.

Safety notes

Generally well-tolerated with minimal systemic effects at research doses

Common side effects: mild headache, nasal irritation, occasional nausea

Monitor electrolytes if exceeding 24 IU daily long-term

May transiently affect blood pressure

Not recommended during pregnancy without medical supervision

Effects on in-group bias noted - be aware of social context

Consult healthcare provider before use, especially with psychiatric conditions

Research studies

Intranasal Oxytocin for Obesity (2024)

Human RCT | N=61 adults with obesity | 24 IU four times daily | 8 weeks | NEJM Evidence

Treatment did not result in weight loss but showed significant reduction in caloric intake at test meals and improvement in mental health-related quality of life. No serious adverse events.

View study →

Oxytocin Effects on Social Cognition in Schizophrenia (2023)

Human RCT | N=68 | 24 IU twice daily | 12 weeks | Schizophrenia Research

While no significant advantage over placebo on primary social cognition outcomes, oxytocin showed modest improvement in social functioning and within-group reduction in negative symptoms.

View study →

Intranasal Oxytocin in Autism Spectrum Disorder (2021)

Human Phase 2 RCT | N=290 children/adolescents | 48 IU daily | 24 weeks | NEJM

Large randomized controlled trial found intranasal oxytocin did not significantly improve social functioning in children and adolescents with ASD compared to placebo, highlighting need for better patient selection and dosing strategies.

View study →

Oxytocin Augmented Prolonged Exposure Therapy for PTSD (2019)

Human RCT | Veterans with PTSD | 40 IU intranasal | Combined with PE therapy

Participants receiving oxytocin demonstrated lower PTSD and depression symptoms during prolonged exposure therapy and reported higher therapeutic alliance scores compared to placebo.

View study →

Chronic Intranasal Oxytocin Effects on Male Sexual Function (2012)

Human case study | 40 IU intranasal | Multi-week chronic use

First documented case of broad-spectrum benefits of chronic intranasal oxytocin on male sexual function including improved libido, erection quality, and orgasm intensity.

View study →